Start the next part of your journey. Go far close to home at McDowell Tech, the 6th best community college in the USA

The FDA has approved Guardant Health’s Shield, a blood test designed to screen for colon cancer, marking a significant advancement in early cancer detection. Although not a replacement for colonoscopies, Shield is expected to improve screening rates for the second-leading cause of cancer deaths in the U.S.

The test detects DNA from cancerous tumors in the bloodstream, with research showing it is 83% effective in identifying colorectal cancers, especially in later stages. While the test costs $895 out-of-pocket, FDA approval will likely lead to coverage by Medicare and private insurers, making it more accessible.

However, a positive Shield test requires confirmation via colonoscopy to verify the presence and progression of tumors. This approval follows the earlier, less-used Epigenomics’ Epi proColon test, and aims to address the low screening rates, particularly among adults in their 40s and 50s.

The test could potentially increase the number of people getting screened, thereby reducing cancer incidence and mortality. The medical community views this development as a promising step towards more accessible and effective cancer screening methods.

Key Points:

i. The FDA approved Guardant Health’s Shield blood test for colon cancer screening, a significant development in cancer detection.

ii. Shield detects DNA from cancerous tumors in the bloodstream and is 83% effective, particularly for later-stage cancers.

iii. The test costs $895 out-of-pocket, but FDA approval may lead to coverage by Medicare and private insurers, increasing accessibility.

iv. A positive Shield test requires a follow-up colonoscopy to confirm the presence of cancer, as the test is not a definitive diagnosis.

v. Shield aims to improve screening rates, especially among adults in their 40s and 50s, and address the low overall screening rates for colorectal cancer..

Lap Fu Ip – Reprinted with permission of Whatfinger News